BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board
LUND, SWEDEN / ACCESSWIRE / October 25, 2021 / BioInvent International (STO:BINV)
- Holds extensive expertise in surgical oncology, immunotherapy, and drug development
- Will provide valuable input as BioInvent further expands clinical pipeline of cancer drugs
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of the renowned immunotherapy expert Alexander Eggermont MD, PhD, as a member of its Scientific Advisory Board.
Prof. Eggermont is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds roles as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology and Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht, the Netherlands. In Germany he is Coordinator at the Comprehensive Cancer Center Program for Deutsche KrebsHilfe and Strategic Advisor at the German Cancer Research Institute (DKFZ), Heidelberg.
"I am delighted to welcome Alexander Eggermont to BioInvent. His extensive experience in immunotherapy and cancer drug development will further strengthen our Scientific Advisory Board and will be invaluable as BioInvent further expands its clinical pipeline of first-in-class immuno-modulatory antibodies for cancer therapies, which currently includes three drug candidates in four ongoing clinical programs," said Martin Welschof, CEO of BioInvent.
Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France and Professor of Oncology (Classe Exceptionelle) at Paris-Saclay University, France. Professor of Surgical Oncology and Endowed Professor of International Networking in Cancer Research at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is a Fellow of the National Institutes of Health's National Cancer Institute (NIH-NCI). He held international positions as President of the European Academy of Cancer Sciences; President of ECCO and President of EORTC.
The other valued members of the BioInvent Scientific Advisory Board are Mark Cragg, Professor of Experimental Cancer Research within Medicine at the University of Southampton, Stephen Beers, Professor of Immunology and Immunotherapy in the Faculty of Medicine at the University of Southampton, Falk Nimmerjahn, Professor in experimental immunology and immune therapy at the Friedrich-Alexander University Erlangen-Nürnberg, Rienk Offringa, Professor at the German Cancer Research Center and Alexander Rudensky, Chair of the Immunology Program at Sloan Kettering Institute.
The main task of the Scientific Advisory Board is to provide BioInvent with valuable input in its effort to develop new antibody treatments for various forms of cancer diseases. The Scientific Advisory Board brings together a wealth of knowledge in the areas of antibody and cancer immunobiology relevant to anti-cancer drug development.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0) 46 286 85 50
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0) 46 286 85 50
SOURCE: BioInvent International
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Episode Six18.1.2022 15:04:37 CET | Press release
Third Anniversary of Episode Six and HSBC's Partnership Shows the Power of Banks and Fintechs Working Together
XPhyto Therapeutics Corp. 17.1.2022 09:06:46 CET | Press release
XPhyto Announces Head of Sales, Europe
Loop Industries, Inc.16.1.2022 22:01:39 CET | Press release
Loop Industries Announces Selection of Port-Jérôme, in Normandy, France, as Site for First European Infinite Loop Manufacturing Facility
XPhyto Therapeutics Corp13.1.2022 09:07:06 CET | Press release
XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia
XPhyto Therapeutics Corp. 10.1.2022 09:06:52 CET | Press release
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
Re:NewCell AB (publ)5.1.2022 11:51:32 CET | Press release
Successful Industrial Scale Viscose Filament Yarn Production from 100 Percent Circulose(R)
STRAX5.1.2022 09:51:36 CET | Press release
STRAX Enters a Partnership to Deliver Covid-19 Tests to Regional Government Body in Europe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom